Hofmeyr G J, Duley L, Atallah A
Effective Care Research Unit, East London Hospital Complex, University of the Witwatersrand/University of Fort Hare, East London, South Africa.
BJOG. 2007 Aug;114(8):933-43. doi: 10.1111/j.1471-0528.2007.01389.x. Epub 2007 Jun 12.
Calcium supplementation during pregnancy may reduce the risk of hypertensive disorders of pregnancy.
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Central Register of Controlled Trials (March 2006).
Randomised trials comparing at least 1 g of calcium daily during pregnancy with placebo. Eligibility and trial quality were assessed.
Data were extracted and analysed using Review Manager software.
Twelve studies (15,528 women) were included, all of good quality. Most women were at low risk and had low dietary calcium. High blood pressure was reduced with calcium supplementation rather than placebo (11 trials, 14,946 women: relative risk [RR] random effects model 0.70; 95% CI 0.57-0.86), as was pre-eclampsia (12 trials, 15,206 women: RR 0.48; 95% CI 0.33-0.69). The effect was greatest for women at high risk (five trials, 587 women: RR 0.22; 95% CI 0.12-0.42) and for those with low baseline calcium intake (seven trials, 10,154 women: RR 0.36; 95% CI 0.18-0.70). There was heterogeneity, with less effect in the larger trials. The composite outcome maternal death or serious morbidity was reduced (four trials, 9732 women: RR 0.80; 95% CI 0.65-0.97). The syndrome of haemolysis, elevated liver enzymes and low platelets was increased (two trials, 12,901 women: RR 2.67; 95% CI 1.05-6.82). There was no overall effect on the risk of preterm birth or stillbirth or death before discharge from hospital.
Calcium supplementation appears to reduce the risk of pre-eclampsia and to reduce the rare occurrence of the composite outcome 'maternal death or serious morbidity'. There were no other clear benefits or harms.
We present the hypothesis that adequate dietary calcium before and in early pregnancy may be needed to prevent the underlying pathology responsible for pre-eclampsia. We suggest that the research agenda be redirected towards calcium supplementation at a community level.
孕期补钙可能降低妊娠期高血压疾病的风险。
我们检索了Cochrane妊娠与分娩组试验注册库以及Cochrane对照试验中央注册库(2006年3月)。
比较孕期每日至少1克钙与安慰剂的随机试验。评估了纳入标准和试验质量。
使用Review Manager软件提取和分析数据。
纳入了12项研究(15528名女性),所有研究质量良好。大多数女性风险较低且膳食钙摄入量低。补钙组的高血压发生率低于安慰剂组(11项研究,14946名女性:随机效应模型的相对风险[RR]为0.70;95%置信区间[CI]为0.57 - 0.86),子痫前期发生率也较低(12项研究,15206名女性:RR为0.48;95% CI为0.33 - 0.69)。对高危女性(5项研究,587名女性:RR为0.22;95% CI为0.12 - 0.42)和基线钙摄入量低的女性(7项研究,10154名女性:RR为0.36;95% CI为0.18 - 0.70)效果最为显著。存在异质性,在较大规模试验中效果较差。孕产妇死亡或严重发病的复合结局有所降低(4项研究,9732名女性:RR为0.80;95% CI为0.65 - 0.97)。溶血、肝酶升高和血小板减少综合征有所增加(2项研究,12901名女性:RR为2.67;95% CI为1.05 - 6.82)。对早产、死产或出院前死亡风险无总体影响。
补钙似乎可降低子痫前期风险,并降低“孕产妇死亡或严重发病”这一罕见复合结局的发生率。无其他明显的益处或危害。
我们提出假说,即孕前及孕早期充足的膳食钙可能是预防子痫前期潜在病理生理过程所必需的。我们建议将研究重点转向社区层面的补钙措施。